Immunome Inc. (IMNM)
NASDAQ (CM) NASDAQ (CM) Primary 
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy
Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.34 per share a year ago.
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade
The consensus price target hints at a 249.9% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Immunome: Transformed Pipeline Offers Multiple Catalysts
Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The company's strong financial position, with a cash runway extending through 2027, supports ongoing clinical development and potential market entry for key assets. Lead assets IM-1021 (ROR1 ADC) and IM-3050 (FAP RLT) entering Phase 1 trials, alongside varegacestat's Phase 3 progress, offer multiple near-term catalysts.
Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.54 per share a year ago.
Immunome Can Take The Fight To Competitors With Varegacestat
Immunome Can Take The Fight To Competitors With Varegacestat
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.36 per share a year ago.
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.46 per share a year ago.
